%PDF-1.4
%
70 0 obj
<>
endobj
67 0 obj
<>
endobj
170 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T12:17:30Z
2024-03-28T18:25:12-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T18:25:12-07:00
application/pdf
Heather
2003-646.jan
uuid:2097bdd9-1dd2-11b2-0a00-cc0927bd7200
uuid:2097bddc-1dd2-11b2-0a00-880000000000
endstream
endobj
56 0 obj
<>
endobj
57 0 obj
<>
endobj
71 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 38 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
202 0 obj
[207 0 R]
endobj
203 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 60.468 737.0293 Tm
[(2.)-875 (W)80 (olfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of)]TJ
1.675 -1.25 Td
(nonsteroidal antiinflammatory drugs. N Engl J Med)Tj
0 Tc 0 Tw 0 -1.25 TD
(1999;340:1888\32099.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875 (Singh G. Recent considerations in nonsteroidal anti-inflammatory)]TJ
0 Tc 1.675 -1.25 Td
[(drug gastropathy)65 (. )55 (Am J Med 1998;105:S31\3208.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875 (Grif)18 (fin MR, Piper JM, Daugherty JR, Snowden M, Ray )18 (W)111 (A.)]TJ
1.675 -1.25 Td
(Nonsteroidal anti-inflammatory drug use and increased risk for)Tj
T*
[(peptic ulcer disease in elderly persons. )55 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
[(1991;1)37 (14:257\32063.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875 (Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious )]TJ
1.675 -1.25 Td
(gastrointestinal complications related to use of nonsteroidal )Tj
T*
[(anti-inflammatory drugs. )55 (A)-220 (meta-analysis. )55 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
[(1991;1)37 (15:787\32096.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875 (Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal )]TJ
1.675 -1.25 Td
(bleeding and perforation associated with individual nonsteroidal)Tj
T*
(anti-inflammatory drugs. Lancet 1994;343:769\32072.)Tj
-1.675 -1.25 Td
[(7.)-875 (Langman MJ, )18 (W)80 (eil J, )18 (W)80 (ainwright P)111 (, et al. Risks of bleeding peptic)]TJ
1.675 -1.25 Td
(ulcer associated with individual non-steroidal anti-inflammatory)Tj
0 Tc T*
(drugs. Lancet 1994;343:1075\3208.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875 (W)80 (olfe F)80 (. )18 (The importance of gastrointestinal \(GI\) symptom severity)]TJ
1.675 -1.25 Td
(in rheumatoid and osteoarthritis: symptom rates and risk for GI)Tj
T*
(hospitalization. J Rheumatol 2000;27:1661\3207.)Tj
-1.675 -1.25 Td
[(9.)-875 (Giercksky KE, Husby G, Rugstad HE. Epidemiology of )]TJ
1.675 -1.25 Td
[(NSAID-related gastrointestinal side ef)18 (fects. Scand J Gastroenterol)]TJ
0 Tc T*
(1989;163 Suppl:3\3208.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875 (Brogden RN, Heel RC, Speight )18 (TM, )55 (A)74 (very GS. Piroxicam. )55 (A)]TJ
2.175 -1.25 Td
[(reappraisal of its pharmacology and therapeutic ef)18 (ficacy)65 (. Drugs)]TJ
0 Tc 0 Tw T*
(1984;28:292\320323.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)37 (1.)-875 (Ofman JJ, MacLean CH, Straus )18 (WL, et al. )55 (A)-220 (metaanalysis of severe)]TJ
2.1381 -1.25 Td
(upper gastrointestinal complications of nonsteroidal )Tj
T*
(antiinflammatory drugs. J Rheumatol 2002;29:804\32012.)Tj
-2.175 -1.25 Td
[(12.)-875 (McKenna F)80 (, )55 (Ar)18 (guelles L, Burke )18 (T)74 (, Lefkowith J, Geis GS. Upper)]TJ
2.175 -1.25 Td
(gastrointestinal tolerability of celecoxib compared with diclofenac)Tj
T*
(in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp)Tj
0 Tc T*
(Rheumatol 2002;20:35\32043.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875 (Kivitz )55 (AJ, Moskowitz R)55 (W)92 (, )18 (W)80 (oods E, et al. Comparative ef)18 (ficacy)]TJ
2.175 -1.25 Td
(and safety of celecoxib and naproxen in the treatment of)Tj
T*
(osteoarthritis of the hip. J Int Med Res 2001;29:467\32079.)Tj
-2.175 -1.25 Td
[(14.)-875 (Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT)74 (, Fries JF)80 (.)]TJ
2.175 -1.25 Td
(Gastrointestinal tract complications of nonsteroidal )Tj
T*
[(anti-inflammatory drug treatment in rheumatoid arthritis. )55 (A)]TJ
T*
[(prospective observational cohort study)65 (. )55 (Arch Intern Med)]TJ
0 Tc 0 Tw T*
(1996;156:1530\3206.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875 (Silverstein FE, Graham DY)129 (, Senior JR, et al. Misoprostol reduces)]TJ
2.175 -1.25 Td
(serious gastrointestinal complications in patients with rheumatoid)Tj
T*
[(arthritis receiving nonsteroidal anti-inflammatory drugs. )55 (A)]TJ
T*
[(randomized, double-blind, placebo-controlled trial. )55 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
(1995;123:241\3209.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875 (Bensen )18 (WG, Zhao SZ, Burke )18 (T)80 (A, et al. Upper gastrointestinal )]TJ
2.175 -1.25 Td
[(tolerability of celecoxib, a COX-2 specific inhibitor)40 (, compared to)]TJ
T*
(naproxen and placebo. J Rheumatol 2000;27:1876\32083.)Tj
-2.175 -1.25 Td
[(17.)-875 (Deeks JJ, Smith LA, Bradley MD. Ef)18 (ficacy)65 (, tolerability)65 (, and upper)]TJ
2.175 -1.25 Td
(gastrointestinal safety of celecoxib for treatment of osteoarthritis)Tj
T*
(and rheumatoid arthritis: systematic review of randomised )Tj
T*
(controlled trials. BMJ 2002;325:619.)Tj
-2.175 -1.25 Td
[(18.)-875 (W)80 (atson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon)]TJ
2.175 -1.25 Td
(TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2)Tj
T*
(\(COX-2\) inhibitor rofecoxib compared with nonselective COX-1)Tj
T*
[(and COX-2 inhibitors in osteoarthritis. )55 (Arch Intern Med)]TJ
0 Tc 0 Tw T*
(2000;160:2998\3203003.)Tj
-0.00011 Tc 0.02499 Tw 30.825 73.75 Td
[(19.)-875 (Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, L)55 (yles M.)]TJ
2.175 -1.25 Td
(Assessing the use of medications in the elderly: methods and initial)Tj
T*
[(experience in the Cardiovascular Health Study)65 (. )18 (The Cardiovascular)]TJ
T*
(Health Study Collaborative Research Group. J Clin Epidemiol)Tj
0 Tc 0 Tw T*
(1992;45:683\32092.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875 (T)70 (alley NJ, Evans JM, Fleming KC, Harmsen )18 (WS, Zinsmeister )55 (AR,)]TJ
2.175 -1.25 Td
(Melton LJ 3rd. Nonsteroidal antiinflammatory drugs and dyspepsia)Tj
0 Tc T*
[(in the elderly)65 (. Dig Dis Sci 1995;40:1345\32050.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875 (W)80 (eisman SM, Graham DY)129 (. Evaluation of the benefits and risks of)]TJ
2.175 -1.25 Td
(low-dose aspirin in the secondary prevention of cardiovascular and)Tj
T*
[(cerebrovascular events. )55 (Arch Intern Med 2002;162:2197\320202.)]TJ
-2.175 -1.25 Td
[(22.)-875 (Guslandi M. Gastric toxicity of antiplatelet therapy with low-dose)]TJ
2.175 -1.25 Td
(aspirin. Drugs 1997;53:1\3205.)Tj
-2.175 -1.25 Td
[(23.)-875 (Savon JJ, )55 (Allen ML, DiMarino )55 (AJ Jr)40 (, Hermann GA, Krum RP)111 (.)]TJ
2.175 -1.25 Td
(Gastrointestinal blood loss with low dose \(325 mg\) plain and)Tj
T*
[(enteric-coated aspirin administration. )55 (Am J Gastroenterol)]TJ
0 Tc 0 Tw T*
(1995;90:581\3205.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875 (W)80 (eil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and)]TJ
2.175 -1.25 Td
(risk of peptic ulcer bleeding. BMJ 1995;310:827\32030.)Tj
-2.175 -1.25 Td
[(25.)-875 (Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug )]TJ
2.175 -1.25 Td
[(gastropathy)65 (. Recognition and response. )55 (Arch Intern Med)]TJ
0 Tc 0 Tw T*
(1987;147:2093\320100.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875 (Cryer B, Feldman M. Ef)18 (fects of very low dose daily)65 (, long-term)]TJ
2.175 -1.25 Td
(aspirin therapy on gastric, duodenal, and rectal prostaglandin levels)Tj
T*
(and on mucosal injury in healthy humans. Gastroenterology)Tj
0 Tc 0 Tw T*
[(1999;1)37 (17:17\32025.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (Whelton )55 (A, Fort JG, Puma JA, Normandin D, Bello )55 (AE, )18 (V)111 (erbur)18 (g)]TJ
2.175 -1.25 Td
(KM. Cyclooxygenase-2\320specific inhibitors and cardiorenal )Tj
T*
(function: a randomized, controlled trial of celecoxib and rofecoxib)Tj
T*
[(in older hypertensive osteoarthritis patients. )55 (Am J )18 (Ther)]TJ
0 Tc 0 Tw T*
(2001;8:85\32095.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875 (Whelton )55 (A, )18 (White )18 (WB, Bello )55 (AE, Puma JA, Fort JG. Ef)18 (fects of)]TJ
2.175 -1.25 Td
(celecoxib and rofecoxib on blood pressure and edema in patients )Tj
/T1_1 1 Tf
0 Tc 0 Tw T*
(\002)Tj
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 0.8238 0 Td
[(65 years of age with systemic hypertension and osteoarthritis. )55 (Am )]TJ
0 Tc -0.8238 -1.25 Td
(J Cardiol 2002;90:959\32063.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875 (Friedenreich CM. Methods for pooled analyses of epidemiologic)]TJ
2.175 -1.25 Td
(studies. Epidemiology 1993;4:295\320302.)Tj
-2.175 -1.25 Td
[(30.)-875 (Zhao SZ, )55 (Ar)18 (guelles LM, Dedhiya SD, Mor)18 (gan DG. Healthcare )]TJ
2.175 -1.25 Td
[(utilization associated with dyspepsia in patients with arthritis. )55 (Am )]TJ
0 Tc T*
(J Manag Care 1999;5:1285\32095.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(31.)-875 (Rampal P)111 (, Moore N, )18 (V)111 (an Ganse E, et al. Gastrointestinal tolerabili-)]TJ
2.175 -1.25 Td
(ty of ibuprofen compared with paracetamol and aspirin at )Tj
T*
[(over)20 (-the-counter doses. J Int Med Res 2002;30:301\3208.)]TJ
-2.175 -1.25 Td
[(32.)-875 (Acevedo E, Castaneda O, Ugaz M, et al. )18 (T)70 (olerability profiles of)]TJ
2.175 -1.25 Td
[(rofecoxib \(V)60 (ioxx\) and )55 (Arthrotec. )55 (A)-220 (comparison of six weeks )]TJ
T*
(treatment in patients with osteoarthritis. Scand J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;30:19\32024.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875 (Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal )]TJ
2.175 -1.25 Td
(toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for)Tj
T*
[(osteoarthritis and rheumatoid arthritis: the CLASS study: )55 (A)]TJ
T*
[(randomized controlled trial. Celecoxib Long-term )55 (Arthritis Safety)]TJ
0 Tc T*
[(Study)65 (. JAMA)-220 (2000;284:1247\32055.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(34.)-875 (Bombardier C, Laine L, Reicin )55 (A, et al. Comparison of upper )]TJ
2.175 -1.25 Td
(gastrointestinal toxicity of rofecoxib and naproxen in patients with)Tj
T*
[(rheumatoid arthritis. )18 (VIGOR Study Group. N Engl J Med)]TJ
0 Tc 0 Tw T*
(2000;343:1520\3208.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(35.)-875 (Singh G, )18 (T)35 (riadafilopoulos G, Fort J. Early onset of improved )]TJ
2.175 -1.25 Td
(moderate or severe upper GI tolerability of celecoxib versus )Tj
T*
(traditional NSAIDs: results from SUCCESS I, a double blind )Tj
T*
[(randomized trial of 13,274 patients [abstract]. )55 (Am J Gastroenterol)]TJ
0 Tc T*
(2002;97 Suppl:S241.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tw 8 0 0 8 545.468 56.4344 Tm
(117)Tj
ET
0 0 0 0 k
53.532 70.507 203 -16.755 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.4861 Tm
(Goldstein, et al: COX inhibitors and OA)Tj
ET
0 0 0 0 k
/GS0 gs
100.882 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
100.882 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_3 8 Tf
106.328 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
50 0 obj
<>stream
8;Z\6=a%\J#ikn#j>p"FOMhuKVT\b0c(m"N9j*,\G(6.!FNbeUT5X6C?QUpc/f]Ae
+4"/2\T=*]%Q?S==hKI_kC&DQVo0-_Q@FQF6gT4K0Zj_p`F/e7%\u573i?OtNpOf,
f.^T=#F^H]`0K.IqJ>FWYKVl(\lOn1]+qZC^pD8[FKZG!rBu+ST?2MXGm#i,Wb5NG
7RMMfB?:eq5fX4j7:n7W%B.[*FdDsdE3,Tq+=a`PmXMa>+_bO
G2?j4dWFCpaa;"7dGOTH/N[/*9gu5.MH$^h1+'_AB5Rgsq2dMq/OOF\J'&h.O?!c<
(Jb@$C4nJW4,l%L/i98U"Y.jXc,As`KJ7q^_J@9fBZuiCfdu291*J#5II_.90*Ruj
V.F)%;4C"+`mcK:*(ZkXridI_&4O*8^i4K"<+ch"F5^Pf.L2SDdC:-oNm?'<7/(i#
Bf>/c'A$e&7))Jn9-`ph%dMlc4B*1c-'rhbl1O&sbVU0Lej7"C=-V`R7
'fr^^(-5/eU&s[E#18Pbj%dCC0SQc5G]>*=UZ.&1hWJ_M'k#5t*>;)H0BphP;Q=%j
1N1ka?O87-i=WW'VQ/e37IU;Sf;&rbjFEP6>Qo]49G'ieJLf2I0""*2Z?D]".,[kcX8[\UV)bmPX;af^WC
,iLb]ojn6p"!Xa;3KDQD"m0j_%I#/6GCr[\]J(M"$dl\[)+OINrm@uhS4bNm%_jMI
8D!?EZ^BP"lZo+PE]s[-b^Zf>~>
endstream
endobj
54 0 obj
[/Indexed/DeviceRGB 255 53 0 R]
endobj
53 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
78 0 obj
<>
endobj
85 0 obj
<>
endobj
79 0 obj
<>
endobj
99 0 obj
<>
endobj
176 0 obj
<>
endobj
80 0 obj
<>
endobj
93 0 obj
<>stream
H{PW/ Q?+U#"tu]DTR!
H GH@@$<(A*li2v/tv?;vwsϙ=3s10B|ք
u$aܻNˠ]0zK-]gb-XW-i7k
%Eb*-,m\2cW᱁+J Rju'Ԇ>}u3#^+$RAڝ'| GQ;J,SB ŧb~ />FPAT*v)EbJhJBX(̋a1-f|b؈3|0N'yhA01ckl1F,-t3&fkf6!+uZku/6-0.xzEN/dqߒKZlz۱NÞou8йg-GqǧNNW&p(ő@s>I1FYY9EHP5zpy FN볫jY'6#NN`~6GbZ6FQV݇>uE!h%Br;
ܾ??zn6ÏJ؟-y䕛g\(JnRT%e+ezYi$39[Qr4
#?bZ4&ʟ{I>htH.rlf2r!մD)LH1|ـ5?k81I[!4q)cƠVeoX߂4yMjg.vW&9~_V+{%=&-XHLB.N^|6Tgeb ᴳi=iBDPQmW'ir5"$]zN{ԉ*7N7t۷m3)16}CK+R ^"